Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024.

Revenue
−0.28%
EPS
−154.6%
Free cash flow
+38.8%
Total debt
−89.4%

Quarter to September 2026, against a year earlier

19.68 0.71 +3.74%
Market cap
$21.8B
P/E
0.0×
Fwd P/E
82.6×
Dividend yield
2.54%
F-score
4/9
Altman Z
0.61
Beneish M
−3.29
Dividend safety
37/100

Viatris Inc. (VTRS) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Viatris Inc. (VTRS) trades at a P/S ratio of 1.5×. Over the past ten years it has ranged from 0.6× (March 2020) to 4.2× (July 2015); the current reading is higher than 69% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.1× and below the Healthcare sector median of 3.5×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2025 1.0× 1.12%
FY2024 1.0× 13.74%
FY2023 0.9× 4.48%
FY2022 0.8× (7.24%)
FY2021 0.9× (3.04%)
FY2020 0.9× 4.64%
FY2019 0.9× (26.90%)
FY2018 1.2× (36.29%)
FY2017 1.9× 6.83%
FY2016 1.8× (33.11%)

Quarterly newest first

Period P/S ratio Change
Sep 2026 1.4× 11.66%
Jun 2026 1.3× 16.94%
Mar 2026 1.1× 5.16%
Dec 2025 1.0× 24.87%
43 more quarters

Against its own ten years

Low 0.6× High 4.2×
Ten-year median 1.0×
Current reading's percentile 75

P/S ratio against peers

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on VTRS